Consolidation therapy for childhood acute lymphoblastic leukemia: Clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide

Cancer Treatment Reviews

Volumn 27, Issue 6, 2001, Pages 339-350

  Estlin, E J ^a   Yule, S M ^b   Lowis, S P ^c  

^a ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^b ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^c BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

Author keywords

Anti metabolite; ara C; Cellular pharmacology; Childhood ALL; CNS; Consolidation; Cyclophosphamide; Etoposide; Pharmacodynamics; Pharmacokinetics; Teniposide

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTILEUKEMIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; ASPARAGINASE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYTARABINE; DEOXYCYTIDINE; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; HYDROCORTISONE; IFOSFAMIDE; METHOTREXATE; NUCLEOSIDE ANALOG; OXAZAPHOSPHORINE DERIVATIVE; TENIPOSIDE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANTINEOPLASTIC ACTIVITY; BOLUS INJECTION; CANCER RECURRENCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PHARMACOLOGY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG INFUSION; DRUG UPTAKE; EXTRACELLULAR FLUID; HUMAN; IN VITRO STUDY; INFANT; LEUKEMIA CELL LINE; LEUKEMIA REMISSION; MOUSE; NONHUMAN; PHARMACODYNAMICS; PROGNOSIS; REVIEW;

EID: 0035734891     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.2002.0244     Document Type: Article

References (93)

1. Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK Medical Research Council trial UKALL X
2. Chemotherapy in 998 unselected childhood acute lymphoblastic leukaemia patients. Results and conclusions of the multicentre trial ALL-BFM 86
3. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukaemia and a slow response to initial therapy
4. Comparative results of two intensive treatment programs for acute lymphoblastic leukaemia: The Berlin-Frankfurt-Munster and Dana-Farber Cancer Institute protocols
5. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation for childhood B-precursor acute lymphoblastic leukaemia: A Pediatric Oncology Group Study
6. Conventional compared with individualised chemotherapy for childhood acute lymphoblastic leukaemia
7. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
8. Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia
9. Cytidine analogues
10. Cytosine arabinosaide transport and metabolism in acute leukaemia and T cell lymphoblastic lymphoma
11. Biochemical and cellular pharmacology of cytosine arabinoside
12. Effects of cytosine arabinosie on human leukaemia cells
13. High molecular weight DNA fragmentation: A critical event in nucleoside analogue-induced apoptosis in leukaemia cells
14. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells form bone marrow and peripheral blood
15. Saturation of 1-β-D-arabinofuranoylcytosine 5′-triphosphate accumulation in leukaemia cells during high-dose 1-β-D-arabinofuranoylcytosine therapy
16. Intracellular retention of cytosine arabinoside triphosphate and blast cells from children with acute myelogenous and lymphoblastic leukaemia
17. Biochemical pharmacology of high dose 1-β-D-arabinofuranosylcytosine in childhood acute leukaemia
18. The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in culture human leukaemia cells
19. Differences in folylpolyglutamyl synthase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukaemic lymphoblasts: Mechanisms for lineage differences in methotrexate polyglutamation and cytotoxicity
20. Apoptosis as a mechanism of cell death induced by different chemotherapeutic drugs in human leukaemic T-lymphocytes
21. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukaemia
22. Oral 6-mercaptopurine in childhood leukaemia: Parent drug pharmacokinetics and active metabolite concentrations
23. Etoposide targets topoisomerase IIalpha and IIbeta in leukaemic cells: Isoform-specific cleavable complexes visualised and quantified in situ by a novel immunofluorescence technique
24. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases II alpha (p170) and II beta (p180)
25. Structure-activity relationships of VP-16 analogues
26. Comparison of caspase activation and sub-cellular localisation in HL-60 and K562 cells undergoing etoposide-induced apoptosis
27. Topoisomerase expression in cancer cells and clinical samples
28. Etoposide-induced DNA cleavage in human leukaemia cells
29. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line
30. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells
31. Exposure and schedule dependency of etoposide in neuroblastoma sand leukaemia cells in vitro
32. Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukaemia
33. Optimal immunocytochemical and flow cytometric detection of P-gp, MRP and LRP in childhood acute lymphoblastic leukaemia
34. Relationship between DNA cross-links, cell cycle and apoptosis in Burkitt's lymphoma cell lines differing in sensitivity to nitrogen mustard
35. Comparison of the sensitivity of normal haematopoetic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo
36. The comparative effects of selected cytotoxic agents on transplanted haematopoietic cells
37. Pharmacokinetics of 'activated' cyclophosphamide and therapeutic efficacies
38. Influence of schedule of alkylating agent cytotoxicity in vitro and in vivo
39. Alkylating agent resistance in paediatric oncology
40. Consolidation therapy with anti-metabolite-based therapy in standard risk acute lymphoblastic leukaemia of childhood: A Pediatric Oncology Group study
41. High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukemia: The Children's Cancer Group experience
42. Extended triple intrathecal chemotherapy trial for prevention of CNS in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukaemia: A Pediatric Oncology Group Study
43. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid
44. Individualised dosages of chemotherapy as a strategy to improve response for acute lymphoblastic leukaemia
45. Pharmacology studies of 1-β-D-arabinofuranosylcytosine in pediatric patients with leukaemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug
46. NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukaemia
47. Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside
48. Pharmacokinetic studies of intermediate-to high-dose 1-beta-D-arabinofuranosylcytosine in children with acute leukaemia and lymphoma
49. Clinical pharmacology of 1-β-D-arabinofuranosylcytosine
50. Pharmacokinetics of teniposide (VM26) and etoposide (VP16-213) in children with cancer
51. Teniposide (VM26) disposition in children with leukaemia
52. A study of the feasibility and accuracy of pharmacologically guided etoposide dosing in children
53. Etoposide achieves potentially cytotoxic concentrations in the CSF of children with acute lymphoblastic leukaemia
54. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T-cell acute lymphoblastic leukaemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group Study
55. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukaemia treated on two consecutive trials of the Children's Cancer Group
56. Cyclophosphamide metabolism in children
57. Cyclophosphamide pharmacokinetics in children
58. Dose escalation of cyclophosphamide in patients with breast cancer: Consequences for pharmacokinetics and metabolism
59. 2 in children with acute lymphoblastic leukaemia
60. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukaemia
61. Pharmacokinetics of HD-MTX in infants, children and adolescents with non-B acute lymphoblastic leukaemia
62. Methotrexate distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections
63. Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in non-toxic patients after lumbar injection
64. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk Non-T, Non-B acute lymphoblastic leukaemia: A Pediatric Oncology group study
65. Pharmacokinetics and distribution of 6-mercaptopurine administered intravenously in children with lymphoblastic leukaemia
66. Cytosine arabinoside. Results of a co-operative study in acute childhood leukaemia
67. Prolonged infusion of arabinosylcytosine in childhood leukaemia
68. A pilot study of high-dose 1-beta-D-aabinofuranosylcytosine for acute leukaemia and refractory lymphoma: Clinical response and pharmacology
69. Continuous infusion high-dose cytosine arabinoside in refractory childhood leukaemia
70. Epipodophyllotoxins in the treatment of childhood cancer
71. VP16-213 (Etoposide). A critical review of its activity
72. Phase II study of VP-16-123 in childhood malignant disease: A Children's Cancer Study Group Report
73. Phase I-II trial of VM-26 (NSC-122819) in the treatment of children with late-stage leukaemia
74. Phase II study of VM-26 in acute leukaemia, neuroblastoma, and other refractory childhood malignancies: A report from the Children's Cancer Study group
75. Cyclophosphamide in the treatment of common neoplastic diseases of childhood
76. Clinical evaluation of cyclophosphamide. A new agent for the treatment of children with acute leukaemia
77. Cyclophosphamide pharmacokinetics: Correlation with cardiac toxicity and tumour response
78. Combination intrathecal therapy for meningeal leukaemia: Two versus three drugs
79. Extended triple intrathecal chemotherapy trial for prevention of CNS in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukaemia: A Pediatric Oncology Group Study
80. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukaemia: Comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: A Children's Cancer Group Report
81. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukaemia
82. The role of vincristine in the treatment of childhood acute leukaemia
83. Association between delivered drug dose and outcome for children with acute lymphoblastic leukaemia and unfavourable presenting features
84. Augmented Berlin-Frankfurt-Munster Therapy Abrogates the Adverse Prognostic Significance of Slow Early Response to Induction Chemotherapy for Children and Adolescents With Acute Lymphoblastic Leukaemia and Features: A Report from the Children's Cancer Group
85. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a Phase I/II study in pediatric patients with relapsed leukaemia
86. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukaemia
87. Use of L-asparaginase in childhood ALL
88. Epipodophyllotoxins, alkylating agents, and radiation risk of secondary leukaemia after childhood cancer
89. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumours
90. Intermittent continuous IV infusion of high-dose cyclophosphamide for remission induction in acute leukaemia
91. Continuous infusion cyclophosphamide plus vincristine cytosine-arabinoside and prednisolone for refractory acute lymphoblastic leukaemia in adults
92. Results of treatment of advanced stage Burkitt's lymphoma and B cell (SIg +) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and co-ordinated high-dose methotrexate and cytarabine
93. The role of pharmacokinetic and phara odynamic studies in the planning of protocols for the treatment of childhood cancer